ResearcherCapital Medical UniversityActive in the last 2 years
Wentong Mei
Matched on OpenAlex author ID A5112735292. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 6
- The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jare.2025.10.079↗
- Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation. Co-author DOI 10.1016/j.intimp.2025.114528↗
- [Exosomes secreted from human umbilical cord mesenchymal stem cells promote pancreatic ductal adenocarcinoma growth by transferring miRNAs]. Co-author DOI 10.3760/cma.j.cn112152-20200622-00586↗
- Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network. Co-author DOI 10.21037/tcr-22-709↗
- Exosomes secreted from human umbilical cord mesenchymal stem cells promote pancreatic ductal adenocarcinoma growth by transferring miR-100-5p. First author DOI 10.1016/j.tice.2021.101623↗
- Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1016/j.canlet.2018.10.039↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yuchen Jia · 4 shared papers, 2021–2026 · strength 0.81
- Paper The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.jare.2025.10.079↗
- Paper Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by … DOI 10.1016/j.intimp.2025.114528↗
- Paper Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network. DOI 10.21037/tcr-22-709↗
- Yixuan Ding · 4 shared papers, 2019–2026 · strength 0.65
- Paper The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.jare.2025.10.079↗
- Paper Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network. DOI 10.21037/tcr-22-709↗
- Paper Exosomes secreted from human umbilical cord mesenchymal stem cells promote pancreatic ductal adenocarcinoma growth by t… DOI 10.1016/j.tice.2021.101623↗
- Fei Li · 2 shared papers, 2025–2026 · strength 0.53
- Paper The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.jare.2025.10.079↗
- Paper Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by … DOI 10.1016/j.intimp.2025.114528↗
- Feng Cao · 3 shared papers, 2019–2022 · strength 0.38
- Paper Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network. DOI 10.21037/tcr-22-709↗
- Paper Exosomes secreted from human umbilical cord mesenchymal stem cells promote pancreatic ductal adenocarcinoma growth by t… DOI 10.1016/j.tice.2021.101623↗
- Paper Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic… DOI 10.1016/j.canlet.2018.10.039↗
- Xiaoqing Xu · 1 shared paper, 2026 · strength 0.27
- Zheng Wang · 1 shared paper, 2025 · strength 0.26
- Yi-Tong Ding · 1 shared paper, 2023 · strength 0.18
- Fei Li · 1 shared paper, 2023 · strength 0.18
- Yuanxu Qu · 1 shared paper, 2022 · strength 0.16
- Fei Li · 1 shared paper, 2022 · strength 0.16
- Yulin Guo · 1 shared paper, 2022 · strength 0.16
- Fei Li · 1 shared paper, 2021 · strength 0.13
- Fei Li · 1 shared paper, 2019 · strength 0.10
- Yecheng Wang · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.